Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials.

摘要: Objective. We performed a systematic review of the literature to evaluate effects alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE EMBASE were searched using key words “lipoic acid’’, “thioctic “diabet*’’, MeSH-terms acid’’ “diabetes mellitus’’. Randomised controlled trials TSS score as outcome measure selected assessed their methodological quality. Study selection quality assessment independently by three observers. Results. Overall, pooled standardized mean difference estimated from all revealed reduction scores −2.26 (CI: −3.12 −1.41; id="x30" d="M241 635q53 94 -28.5t63.5 -76t33.5 -102.5t11 -116q0 -58 -11 -112.5t-34 -103.5t-63.5 -78.5t-94.5 -29.5t-95 28t-64.5 75t-34.5 102.5t-11 118.5q0 58 11.5 112.5t34.5 103t64.5 78t95.5 29.5zM238 602q-32 -55.5 -25t-35.5 -68t-17.5 -91t-5.5 -105 q0 -76 10 -138.5t37 -107.5t69 -45q32 55.5 25t35.5 68.5t17.5 91.5t5.5 105t-5.5 105.5t-18 92t-36 68t-56.5 24.5z"/> ) favour administration. Subgroup analyses oral administration (−1.78 CI: −2.45 −1.10; intravenous (−2.81 −4.16 −1.46; confirmed robustness overall result. Conclusions. When given intravenously at dosage 600 mg/day over period 3 weeks, leads significant clinically relevant neuropathic pain (grade recommendation A). It is unclear if improvements seen after 3–5 weeks > are relevant.